

Global GLP-1 Combination and Multi-agonist Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GBBE9F8B70DCEN.html>

Date: July 2026

Pages: 105

Price: US\$ 3,480.00 (Single User License)

ID: GBBE9F8B70DCEN

Abstracts

According to our (Global Info Research) latest study, the global GLP-1 Combination and Multi-agonist Drugs market size was valued at US\$ 19288 million in 2025 and is forecast to a readjusted size of US\$ 61694 million by 2032 with a CAGR of 17.1% during review period.

GLP-1 combination and multi-agonist drugs are innovative medicines built around the GLP-1 pathway while also engaging GIP, glucagon, amylin or other metabolic targets to improve body weight, glucose control, fatty liver disease and cardiometabolic risk through synergistic mechanisms. The category includes dual agonists, tri-agonists, fixed-dose combinations and combination candidates, with evaluation focused on greater weight reduction, broader metabolic benefit, safety, dosing convenience and long-term adherence. In 2025, global GLP-1 Combination and Multi-agonist Drugs production reached approximately 320 million unit. The average gross profit margin of this product is 80%.

GLP-1 combination and multi-agonist drugs are among the most active innovation areas in obesity and metabolic disease. Dual- and tri-target mechanisms may further improve weight-loss efficacy beyond traditional GLP-1 therapy and expand use into diabetes, MASH and broader cardiometabolic risk management.

Industrial competition is concentrated among large global pharmaceutical companies and selected innovative biotechnology firms. Approved dual agonists have accelerated market education and physician adoption, while late-stage tri-agonists, GLP-1/glucagon dual agonists and amylin combinations may drive the next wave of differentiation.

Growth is influenced by clinical trial outcomes, long-term safety, capacity scale-up, drug pricing and payer coverage. Future market focus will shift toward the upper limit of efficacy, muscle-mass preservation, post-treatment weight management, liver metabolic improvement and integrated chronic disease care.

This report is a detailed and comprehensive analysis for global GLP-1 Combination and Multi-agonist Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global GLP-1 Combination and Multi-agonist Drugs market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global GLP-1 Combination and Multi-agonist Drugs market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global GLP-1 Combination and Multi-agonist Drugs market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global GLP-1 Combination and Multi-agonist Drugs market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for GLP-1 Combination and Multi-agonist Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global GLP-1 Combination and Multi-agonist Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi, GSK, Hansoh, HuiRen Bio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

GLP-1 Combination and Multi-agonist Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

GIP/GLP-1 Dual Agonist

GLP-1/Glucagon Dual Agonist

Amylin/GLP-1 Combination

GIP/GLP-1/Glucagon Tri-agonist

GLP-1 Plus Small Molecule

Other

Market segment by Indication

Obesity

Type 2 Diabetes

MASH

Cardiometabolic Disease

Other

Market segment by Dosage Form

Peptide Injection

Long-acting Injection

Oral Candidate

Combination Kit

Other

Market segment by Application

Obesity Clinics

Endocrinology Departments

Metabolic Disease Centers

Clinical Trial Sites

Hospital Pharmacies

Retail Pharmacies

Other

Major players covered

Eli Lilly

Novo Nordisk

Boehringer Ingelheim

AstraZeneca

Sanofi

GSK

Hansoh

Huiren Bio

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe GLP-1 Combination and Multi-agonist Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of GLP-1 Combination and Multi-

agonist Drugs, with price, sales quantity, revenue, and global market share of GLP-1 Combination and Multi-agonist Drugs from 2021 to 2026.

Chapter 3, the GLP-1 Combination and Multi-agonist Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the GLP-1 Combination and Multi-agonist Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and GLP-1 Combination and Multi-agonist Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Combination and Multi-agonist Drugs.

Chapter 14 and 15, to describe GLP-1 Combination and Multi-agonist Drugs sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global GLP-1 Combination and Multi-agonist Drugs Consumption
Value by Type: 2021 Versus 2025 Versus 2032

1.3.2 GIP/GLP-1 Dual Agonist

1.3.3 GLP-1/Glucagon Dual Agonist

1.3.4 Amylin/GLP-1 Combination

1.3.5 GIP/GLP-1/Glucagon Tri-agonist

1.3.6 GLP-1 Plus Small Molecule

1.3.7 Other

1.4 Market Analysis by Indication

1.4.1 Overview: Global GLP-1 Combination and Multi-agonist Drugs Consumption
Value by Indication: 2021 Versus 2025 Versus 2032

1.4.2 Obesity

1.4.3 Type 2 Diabetes

1.4.4 MASH

1.4.5 Cardiometabolic Disease

1.4.6 Other

1.5 Market Analysis by Dosage Form

1.5.1 Overview: Global GLP-1 Combination and Multi-agonist Drugs Consumption
Value by Dosage Form: 2021 Versus 2025 Versus 2032

1.5.2 Peptide Injection

1.5.3 Long-acting Injection

1.5.4 Oral Candidate

1.5.5 Combination Kit

1.5.6 Other

1.6 Market Analysis by Application

1.6.1 Overview: Global GLP-1 Combination and Multi-agonist Drugs Consumption
Value by Application: 2021 Versus 2025 Versus 2032

1.6.2 Obesity Clinics

1.6.3 Endocrinology Departments

1.6.4 Metabolic Disease Centers

1.6.5 Clinical Trial Sites

1.6.6 Hospital Pharmacies

1.6.7 Retail Pharmacies

1.6.8 Other

1.7 Global GLP-1 Combination and Multi-agonist Drugs Market Size & Forecast

1.7.1 Global GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021 & 2025 & 2032)

1.7.2 Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity (2021-2032)

1.7.3 Global GLP-1 Combination and Multi-agonist Drugs Average Price (2021-2032)

2 MANUFACTURERS PROFILES

2.1 Eli Lilly

2.1.1 Eli Lilly Details

2.1.2 Eli Lilly Major Business

2.1.3 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product and Services

2.1.4 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 Eli Lilly Recent Developments/Updates

2.2 Novo Nordisk

2.2.1 Novo Nordisk Details

2.2.2 Novo Nordisk Major Business

2.2.3 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product and Services

2.2.4 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.2.5 Novo Nordisk Recent Developments/Updates

2.3 Boehringer Ingelheim

2.3.1 Boehringer Ingelheim Details

2.3.2 Boehringer Ingelheim Major Business

2.3.3 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product and Services

2.3.4 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.3.5 Boehringer Ingelheim Recent Developments/Updates

2.4 AstraZeneca

2.4.1 AstraZeneca Details

2.4.2 AstraZeneca Major Business

2.4.3 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product and Services

2.4.4 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.4.5 AstraZeneca Recent Developments/Updates

2.5 Sanofi

2.5.1 Sanofi Details

2.5.2 Sanofi Major Business

2.5.3 Sanofi GLP-1 Combination and Multi-agonist Drugs Product and Services

2.5.4 Sanofi GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.5.5 Sanofi Recent Developments/Updates

2.6 GSK

2.6.1 GSK Details

2.6.2 GSK Major Business

2.6.3 GSK GLP-1 Combination and Multi-agonist Drugs Product and Services

2.6.4 GSK GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.6.5 GSK Recent Developments/Updates

2.7 Hansoh

2.7.1 Hansoh Details

2.7.2 Hansoh Major Business

2.7.3 Hansoh GLP-1 Combination and Multi-agonist Drugs Product and Services

2.7.4 Hansoh GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.7.5 Hansoh Recent Developments/Updates

2.8 Huiren Bio

2.8.1 Huiren Bio Details

2.8.2 Huiren Bio Major Business

2.8.3 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Product and Services

2.8.4 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.8.5 Huiren Bio Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: GLP-1 COMBINATION AND MULTI-AGONIST DRUGS BY MANUFACTURER

3.1 Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Manufacturer (2021-2026)

3.2 Global GLP-1 Combination and Multi-agonist Drugs Revenue by Manufacturer (2021-2026)

3.3 Global GLP-1 Combination and Multi-agonist Drugs Average Price by Manufacturer (2021-2026)

3.4 Market Share Analysis (2025)

3.4.1 Producer Shipments of GLP-1 Combination and Multi-agonist Drugs by Manufacturer Revenue (\$MM) and Market Share (%): 2025

3.4.2 Top 3 GLP-1 Combination and Multi-agonist Drugs Manufacturer Market Share in 2025

3.4.3 Top 6 GLP-1 Combination and Multi-agonist Drugs Manufacturer Market Share in 2025

3.5 GLP-1 Combination and Multi-agonist Drugs Market: Overall Company Footprint Analysis

3.5.1 GLP-1 Combination and Multi-agonist Drugs Market: Region Footprint

3.5.2 GLP-1 Combination and Multi-agonist Drugs Market: Company Product Type Footprint

3.5.3 GLP-1 Combination and Multi-agonist Drugs Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global GLP-1 Combination and Multi-agonist Drugs Market Size by Region

4.1.1 Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Region (2021-2032)

4.1.2 Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Region (2021-2032)

4.1.3 Global GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2021-2032)

4.2 North America GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032)

4.3 Europe GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032)

4.4 Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032)

4.5 South America GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032)

4.6 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032)

5 MARKET SEGMENT BY TYPE

5.1 Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type

(2021-2032)

5.2 Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Type
(2021-2032)

5.3 Global GLP-1 Combination and Multi-agonist Drugs Average Price by Type
(2021-2032)

6 MARKET SEGMENT BY APPLICATION

6.1 Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application
(2021-2032)

6.2 Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by
Application (2021-2032)

6.3 Global GLP-1 Combination and Multi-agonist Drugs Average Price by Application
(2021-2032)

7 NORTH AMERICA

7.1 North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type
(2021-2032)

7.2 North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by
Application (2021-2032)

7.3 North America GLP-1 Combination and Multi-agonist Drugs Market Size by Country
7.3.1 North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by
Country (2021-2032)

7.3.2 North America GLP-1 Combination and Multi-agonist Drugs Consumption Value
by Country (2021-2032)

7.3.3 United States Market Size and Forecast (2021-2032)

7.3.4 Canada Market Size and Forecast (2021-2032)

7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

8.1 Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type
(2021-2032)

8.2 Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application
(2021-2032)

8.3 Europe GLP-1 Combination and Multi-agonist Drugs Market Size by Country

8.3.1 Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country
(2021-2032)

8.3.2 Europe GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2021-2032)

8.3.3 Germany Market Size and Forecast (2021-2032)

8.3.4 France Market Size and Forecast (2021-2032)

8.3.5 United Kingdom Market Size and Forecast (2021-2032)

8.3.6 Russia Market Size and Forecast (2021-2032)

8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

9.1 Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2032)

9.2 Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2021-2032)

9.3 Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Market Size by Region

9.3.1 Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Region (2021-2032)

9.3.2 Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Consumption Value by Region (2021-2032)

9.3.3 China Market Size and Forecast (2021-2032)

9.3.4 Japan Market Size and Forecast (2021-2032)

9.3.5 South Korea Market Size and Forecast (2021-2032)

9.3.6 India Market Size and Forecast (2021-2032)

9.3.7 Southeast Asia Market Size and Forecast (2021-2032)

9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

10.1 South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2032)

10.2 South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2021-2032)

10.3 South America GLP-1 Combination and Multi-agonist Drugs Market Size by Country

10.3.1 South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2021-2032)

10.3.2 South America GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2021-2032)

10.3.3 Brazil Market Size and Forecast (2021-2032)

10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2032)

11.2 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2021-2032)

11.3 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Market Size by Country

11.3.1 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2021-2032)

11.3.2 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2021-2032)

11.3.3 Turkey Market Size and Forecast (2021-2032)

11.3.4 Egypt Market Size and Forecast (2021-2032)

11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)

11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

12.1 GLP-1 Combination and Multi-agonist Drugs Market Drivers

12.2 GLP-1 Combination and Multi-agonist Drugs Market Restraints

12.3 GLP-1 Combination and Multi-agonist Drugs Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of GLP-1 Combination and Multi-agonist Drugs and Key Manufacturers

13.2 Manufacturing Costs Percentage of GLP-1 Combination and Multi-agonist Drugs

13.3 GLP-1 Combination and Multi-agonist Drugs Production Process

13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 GLP-1 Combination and Multi-agonist Drugs Typical Distributors

14.3 GLP-1 Combination and Multi-agonist Drugs Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032

Table 3. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032

Table 4. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Eli Lilly Basic Information, Manufacturing Base and Competitors

Table 6. Eli Lilly Major Business

Table 7. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product and Services

Table 8. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. Eli Lilly Recent Developments/Updates

Table 10. Novo Nordisk Basic Information, Manufacturing Base and Competitors

Table 11. Novo Nordisk Major Business

Table 12. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product and Services

Table 13. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. Novo Nordisk Recent Developments/Updates

Table 15. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors

Table 16. Boehringer Ingelheim Major Business

Table 17. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product and Services

Table 18. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Boehringer Ingelheim Recent Developments/Updates

Table 20. AstraZeneca Basic Information, Manufacturing Base and Competitors

Table 21. AstraZeneca Major Business

Table 22. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product and

Services

Table 23. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 24. AstraZeneca Recent Developments/Updates

Table 25. Sanofi Basic Information, Manufacturing Base and Competitors

Table 26. Sanofi Major Business

Table 27. Sanofi GLP-1 Combination and Multi-agonist Drugs Product and Services

Table 28. Sanofi GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 29. Sanofi Recent Developments/Updates

Table 30. GSK Basic Information, Manufacturing Base and Competitors

Table 31. GSK Major Business

Table 32. GSK GLP-1 Combination and Multi-agonist Drugs Product and Services

Table 33. GSK GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 34. GSK Recent Developments/Updates

Table 35. Hansoh Basic Information, Manufacturing Base and Competitors

Table 36. Hansoh Major Business

Table 37. Hansoh GLP-1 Combination and Multi-agonist Drugs Product and Services

Table 38. Hansoh GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 39. Hansoh Recent Developments/Updates

Table 40. HuiRen Bio Basic Information, Manufacturing Base and Competitors

Table 41. HuiRen Bio Major Business

Table 42. HuiRen Bio GLP-1 Combination and Multi-agonist Drugs Product and Services

Table 43. HuiRen Bio GLP-1 Combination and Multi-agonist Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 44. HuiRen Bio Recent Developments/Updates

Table 45. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Manufacturer (2021-2026) & (K Units)

Table 46. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Manufacturer (2021-2026) & (USD Million)

Table 47. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 48. Market Position of Manufacturers in GLP-1 Combination and Multi-agonist Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 49. Head Office and GLP-1 Combination and Multi-agonist Drugs Production Site of Key Manufacturer

Table 50. GLP-1 Combination and Multi-agonist Drugs Market: Company Product Type Footprint

Table 51. GLP-1 Combination and Multi-agonist Drugs Market: Company Product Application Footprint

Table 52. GLP-1 Combination and Multi-agonist Drugs New Market Entrants and Barriers to Market Entry

Table 53. GLP-1 Combination and Multi-agonist Drugs Mergers, Acquisition, Agreements, and Collaborations

Table 54. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 55. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Region (2021-2026) & (K Units)

Table 56. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Region (2027-2032) & (K Units)

Table 57. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Region (2021-2026) & (USD Million)

Table 58. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Region (2027-2032) & (USD Million)

Table 59. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2021-2026) & (US\$/Unit)

Table 60. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2027-2032) & (US\$/Unit)

Table 61. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 62. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 63. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Type (2021-2026) & (USD Million)

Table 64. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Type (2027-2032) & (USD Million)

Table 65. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2026) & (US\$/Unit)

Table 66. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2027-2032) & (US\$/Unit)

Table 67. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by

Application (2021-2026) & (K Units)

Table 68. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 69. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Application (2021-2026) & (USD Million)

Table 70. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Application (2027-2032) & (USD Million)

Table 71. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2026) & (US\$/Unit)

Table 72. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2027-2032) & (US\$/Unit)

Table 73. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 74. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 75. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 76. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 77. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2021-2026) & (K Units)

Table 78. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2027-2032) & (K Units)

Table 79. North America GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 80. North America GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 81. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 82. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 83. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 84. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 85. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2021-2026) & (K Units)

Table 86. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2027-2032) & (K Units)

Table 87. Europe GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 88. Europe GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 89. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 90. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 91. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 92. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 93. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Region (2021-2026) & (K Units)

Table 94. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Region (2027-2032) & (K Units)

Table 95. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Consumption Value by Region (2021-2026) & (USD Million)

Table 96. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Consumption Value by Region (2027-2032) & (USD Million)

Table 97. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 98. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 99. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 100. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 101. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2021-2026) & (K Units)

Table 102. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Country (2027-2032) & (K Units)

Table 103. South America GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 104. South America GLP-1 Combination and Multi-agonist Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 105. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 106. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales

Quantity by Type (2027-2032) & (K Units)

Table 107. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales

Quantity by Application (2021-2026) & (K Units)

Table 108. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales

Quantity by Application (2027-2032) & (K Units)

Table 109. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales

Quantity by Country (2021-2026) & (K Units)

Table 110. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales

Quantity by Country (2027-2032) & (K Units)

Table 111. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs

Consumption Value by Country (2021-2026) & (USD Million)

Table 112. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs

Consumption Value by Country (2027-2032) & (USD Million)

Table 113. GLP-1 Combination and Multi-agonist Drugs Raw Material

Table 114. Key Manufacturers of GLP-1 Combination and Multi-agonist Drugs Raw
Materials

Table 115. GLP-1 Combination and Multi-agonist Drugs Typical Distributors

Table 116. GLP-1 Combination and Multi-agonist Drugs Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. GLP-1 Combination and Multi-agonist Drugs Picture
- Figure 2. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Type in 2025
- Figure 4. GIP/GLP-1 Dual Agonist Examples
- Figure 5. GLP-1/Glucagon Dual Agonist Examples
- Figure 6. Amylin/GLP-1 Combination Examples
- Figure 7. GIP/GLP-1/Glucagon Tri-agonist Examples
- Figure 8. GLP-1 Plus Small Molecule Examples
- Figure 9. Other Examples
- Figure 10. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Indication, (USD Million), 2021 & 2025 & 2032
- Figure 11. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Indication in 2025
- Figure 12. Obesity Examples
- Figure 13. Type 2 Diabetes Examples
- Figure 14. MASH Examples
- Figure 15. Cardiometabolic Disease Examples
- Figure 16. Other Examples
- Figure 17. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
- Figure 18. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Dosage Form in 2025
- Figure 19. Peptide Injection Examples
- Figure 20. Long-acting Injection Examples
- Figure 21. Oral Candidate Examples
- Figure 22. Combination Kit Examples
- Figure 23. Other Examples
- Figure 24. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 25. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Application in 2025
- Figure 26. Obesity Clinics Examples
- Figure 27. Endocrinology Departments Examples

Figure 28. Metabolic Disease Centers Examples

Figure 29. Clinical Trial Sites Examples

Figure 30. Hospital Pharmacies Examples

Figure 31. Retail Pharmacies Examples

Figure 32. Other Examples

Figure 33. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 34. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 35. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity (2021-2032) & (K Units)

Figure 36. Global GLP-1 Combination and Multi-agonist Drugs Price (2021-2032) & (US\$/Unit)

Figure 37. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Manufacturer in 2025

Figure 38. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Manufacturer in 2025

Figure 39. Producer Shipments of GLP-1 Combination and Multi-agonist Drugs by Manufacturer Sales (\$MM) and Market Share (%): 2025

Figure 40. Top 3 GLP-1 Combination and Multi-agonist Drugs Manufacturer (Revenue) Market Share in 2025

Figure 41. Top 6 GLP-1 Combination and Multi-agonist Drugs Manufacturer (Revenue) Market Share in 2025

Figure 42. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Region (2021-2032)

Figure 43. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value Market Share by Region (2021-2032)

Figure 44. North America GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 45. Europe GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 46. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 47. South America GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 48. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 49. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Type (2021-2032)

Figure 50. Global GLP-1 Combination and Multi-agonist Drugs Consumption Value Market Share by Type (2021-2032)

Figure 51. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2032) & (US\$/Unit)

Figure 52. Global GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 53. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Application (2021-2032)

Figure 54. Global GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2032) & (US\$/Unit)

Figure 55. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Type (2021-2032)

Figure 56. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 57. North America GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Country (2021-2032)

Figure 58. North America GLP-1 Combination and Multi-agonist Drugs Consumption Value Market Share by Country (2021-2032)

Figure 59. United States GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 60. Canada GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 61. Mexico GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 62. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Type (2021-2032)

Figure 63. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 64. Europe GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Country (2021-2032)

Figure 65. Europe GLP-1 Combination and Multi-agonist Drugs Consumption Value Market Share by Country (2021-2032)

Figure 66. Germany GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 67. France GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 68. United Kingdom GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 69. Russia GLP-1 Combination and Multi-agonist Drugs Consumption Value

(2021-2032) & (USD Million)

Figure 70. Italy GLP-1 Combination and Multi-agonist Drugs Consumption Value
(2021-2032) & (USD Million)

Figure 71. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity
Market Share by Type (2021-2032)

Figure 72. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity
Market Share by Application (2021-2032)

Figure 73. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Sales Quantity
Market Share by Region (2021-2032)

Figure 74. Asia-Pacific GLP-1 Combination and Multi-agonist Drugs Consumption Value
Market Share by Region (2021-2032)

Figure 75. China GLP-1 Combination and Multi-agonist Drugs Consumption Value
(2021-2032) & (USD Million)

Figure 76. Japan GLP-1 Combination and Multi-agonist Drugs Consumption Value
(2021-2032) & (USD Million)

Figure 77. South Korea GLP-1 Combination and Multi-agonist Drugs Consumption
Value (2021-2032) & (USD Million)

Figure 78. India GLP-1 Combination and Multi-agonist Drugs Consumption Value
(2021-2032) & (USD Million)

Figure 79. Southeast Asia GLP-1 Combination and Multi-agonist Drugs Consumption
Value (2021-2032) & (USD Million)

Figure 80. Australia GLP-1 Combination and Multi-agonist Drugs Consumption Value
(2021-2032) & (USD Million)

Figure 81. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity
Market Share by Type (2021-2032)

Figure 82. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity
Market Share by Application (2021-2032)

Figure 83. South America GLP-1 Combination and Multi-agonist Drugs Sales Quantity
Market Share by Country (2021-2032)

Figure 84. South America GLP-1 Combination and Multi-agonist Drugs Consumption
Value Market Share by Country (2021-2032)

Figure 85. Brazil GLP-1 Combination and Multi-agonist Drugs Consumption Value
(2021-2032) & (USD Million)

Figure 86. Argentina GLP-1 Combination and Multi-agonist Drugs Consumption Value
(2021-2032) & (USD Million)

Figure 87. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales
Quantity Market Share by Type (2021-2032)

Figure 88. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales
Quantity Market Share by Application (2021-2032)

Figure 89. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Quantity Market Share by Country (2021-2032)

Figure 90. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Consumption Value Market Share by Country (2021-2032)

Figure 91. Turkey GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 92. Egypt GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 93. Saudi Arabia GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 94. South Africa GLP-1 Combination and Multi-agonist Drugs Consumption Value (2021-2032) & (USD Million)

Figure 95. GLP-1 Combination and Multi-agonist Drugs Market Drivers

Figure 96. GLP-1 Combination and Multi-agonist Drugs Market Restraints

Figure 97. GLP-1 Combination and Multi-agonist Drugs Market Trends

Figure 98. Porters Five Forces Analysis

Figure 99. Manufacturing Cost Structure Analysis of GLP-1 Combination and Multi-agonist Drugs in 2025

Figure 100. Manufacturing Process Analysis of GLP-1 Combination and Multi-agonist Drugs

Figure 101. GLP-1 Combination and Multi-agonist Drugs Industrial Chain

Figure 102. Sales Channel: Direct to End-User vs Distributors

Figure 103. Direct Channel Pros & Cons

Figure 104. Indirect Channel Pros & Cons

Figure 105. Methodology

Figure 106. Research Process and Data Source

I would like to order

Product name: Global GLP-1 Combination and Multi-agonist Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GBBE9F8B70DCEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBBE9F8B70DCEN.html>